BioNotebook: Three licenses and a royalty deal; Ligand/Avion, RedHill/RESprotect and more
This article was originally published in Scrip
Executive Summary
Summer is for relaxing, but biotechnology companies like Avion Pharmaceuticals and investors like DRI Capital remain focused on licensing key programs or buying new revenue streams.